FDA approves CAR-T cell therapy to treat adults with certain types of large B-cell lymphoma
Yescarta is the second gene therapy product approved in the U.S.
The U.S. Food and Drug Administration today approved Yescarta (axicabtagene ciloleucel), a cell-based gene therapy, to treat adult patients with certain types of large B-cell lymphoma who have not responded to or who have relapsed after at least two other kinds of treatment. Yescarta, a chimeric antigen receptor (CAR) T cell therapy, is the second gene therapy approved by the FDA and the first for certain types of non-Hodgkin lymphoma (NHL).
This is a preview of YESCARTA | Groundbreaking Approval for 2nd CAR-T technology for non-Hodgkin lymphoma (NHL). Read the full post (781 words, 2 images, estimated 3:07 mins reading time)
The researchers at Johns Hopkins University School of Medicine are conducting a new study for manufacturing personalized medicine with the help of protein markers for varied level of Phosphorylation.
A form of heart disease known as heart failure with preserved ejection fraction (the amount of blood squeezed out when the heart contracts) impairs the heart’s ability to quickly and efficiently relax between “beats,” overworking the organ. The disease is estimated to impair circulation in more than 23 million people worldwide. Patients with ejection fraction issue preserved at baseline have particular difficulty when they try to increase their activity or exercise unlike the usual issue of shortness of breath that occurs in the other types of heart disorders.
This is a preview of Inhibiting the protein involved in Phosphorylation may treat Heart disorders. Read the full post (528 words, estimated 2:07 mins reading time)
A post-doctoral position is open to study the link between emotions and the neural monitoring of visceral inputs. This project is part of a broader ERC project testing thehypothesis that the neural monitoring of visceral inputs (heart, stomach) generates a subject-centered reference frame, from which first-person perspective can develop, in perception, cognition and emotion.
Motivated candidates with an excellent academic record in affective neuroscience and good programming abilities are welcome to apply. Knowledge of, and/or experience with, brain imaging and physiological recordings would be a strong plus. The position is initially funded for two years, beginning in January 2018 (flexible). The successful candidate will benefit from the interdisciplinary environment and computing resources of the Cognitive Neuroscience Laboratory, Department of Cognitive Science at Ecole Normale Supérieure in central Paris, as well as from the state-of-the-art neuroimaging facility (MEG, fMRI, TMS, intracranial EEG) at nearby Hôpital Pitié-Salpêtrière.
Informal enquiries and formal applications (CV, motivation letter and contact details of at least 2 references) should be sent to email@example.com. The position is open until filled.
This is a preview of Post-doctoral position, Paris: neural monitoring of visceral inputs and emotions. Read the full post (178 words, estimated 43 secs reading time)
Introduction to Theranostics
Theranostics is a field of medicine that refers to a combination of diagnostic imaging and therapy to treat various types of cancers. Theranostics = Therapy + Diagnostics. Patients are imaged and depending on the tumour size and spread, are identified for therapy. The therapy is given by localized radiation delivered only to the diseased region, reducing the impact on surrounding healthy cells.
Principle of Theranostics
How does it work?
- Radioactive compound is attached to a linking molecule that is bound to the binding molecule, which attaches to the cancer cell.
Respiratory health is deteriorating day by day globally due to an increased exposure to certain risk factors such as pollution, smoking and passive lifestyle. Although in general the respiratory diseases can be kept under control, there is still a need for better phenotyping and management of lung diseases such as COPD and Asthma. The conventional Lung Function Tests like spirometry don’t provide any regional information and have limited sensitivity to detect changes in pulmonary function in an early stage because the healthy areas in the lung compensate for a progressive disease making it undetectable. There is a need to shift to a better technology which can look at the overall lung health.
This is a preview of Functional Respiratory Imaging (FRI)- A Novel Approach To Assess Lung Health. Read the full post (361 words, 1 image, estimated 1:27 mins reading time)